home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops  
 

Understanding the Scope of FDA’s Inspection Authority and Its Ability to Access Company Records

 
  December 03, 2012  
     
 
ComplianceOnline, Online Event
2012-12-12


Why Should You Attend:

Companies that manufacture products regulated by the USFDA are subject to inspection by the Agency, although the scope of FDA’s authority varies with the type of product being produced. Nevertheless, FDA investigators are trained to ask for information to which they are not legally entitled, in the hope that companies will provide such information “voluntarily.” Company personnel need to understand these limits (and how to respond when FDA tries to go beyond them) to protect their businesses.

This session is designed for manufacturers of foods, dietary supplements, cosmetics, pharmaceuticals, and medical devices. It will provide a clear overview of the extent of FDA’s inspection authority and what limits apply to different categories of products. It will also present many practical considerations to help companies prepare for an FDA inspection, deal with inspectors who may try to push the limits, and know when it may be appropriate to take firm stand against providing certain information.

Areas Covered in the Webinar:

  • Scope of FDA’s inspection authority for different categories of products.
  • How to prepare for an inspection and steps to take to ensure that the event is handled correctly and efficiently.
  • Keys to setting the tone for the inspection once the investigator has arrived.
  • Successfully pushing back against FDA requests to take photographs or have access to excluded information.
  • Considering when it may benefit the company to provide more information voluntarily.
  • One thing not to do when asked by an FDA investigator.
 
 
Organized by: ComplianceOnline
Invited Speakers: Frederick A. Stearns, is a partner in the law firm of Keller and Heckman LLP’s Washington, DC, office, where his practice involves a wide range of issues facing manufacturers of prescription and over-the-counter drugs, medical devices, dietary supplements, and cosmetics. He helps product manufacturers evaluate the need for marketing approval from FDA, pursue appropriate clearance when necessary, and address regulatory compliance issues with marketed products (including OTC drug monographs, product labeling and promotion, and current good manufacturing practices).
 
Deadline for Abstracts: 2012-12-12
 
Registration: http://www.complianceonline.com/ecommerce/control/trainingFocus/~product_id=702580?channel=hum-molgen
E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.